u/ignacio_vanhecke

Strongly agree. Tirz is better than sema is not a claim without a comparator dose.

the 503A/503B distinction is load-bearing, do not blur it

Adding to this: API source is doing more work than the comment implies.

The related substances profile is way more interesting than the main peak %. A 98% with 8 peaks is different from a 98% that is one 3% impurity.

the GIP side does different things than the GLP-1 side, that is the point

This is the "correlation is mechanism" thing again. You changed three variables at once.

regulatory claims need a citation to the actual rule, not interpretation

Asked 13 compounders about API source. One told me, one dodged, one said they cannot say. The answer is the signal.

The telehealth + compounding combo cost 503A plus 19% markup. Not cheap but covered by insurance depending on state.

nope, the equivalence to semaglutide is not known, comparing 15mg tirz to 2.4mg sema is guessing

the reflux from tirz is different, not necessarily worse

The dual agonism story is real. The appetite is physically different from semaglutide alone.

What was the column and what gradient?

This is correct. PBS listings matter.

seizure and reship are different outcomes

do not suggest misrepresenting a diagnosis, that is fraud